NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) — Cyborg Score 7/10
Strong
Pharmaceuticals
Strategic Profile
DA-1726 is a dual oxyntomodulin analog that activates GLP1R and GCGR receptors, designed to achieve superior weight loss by reducing food intake while increasing energy expenditure compared to selective GLP1R agonists. The company remains well-funded following a June 2024 financing of up to $70 million.
Cyborg Score Rationale
Clinical-stage biotech with two promising asset programs targeting large cardiometabolic markets (obesity and MASH). Pipeline shows positive Phase 1 data for lead candidate. Recent strategic repositioning and adequate funding support advancement through 2026 milestones.
Top Insights
Company rebranded from NeuroBo Pharmaceuticals to MetaVia Inc. effective November 29, 2024, with ticker symbol changing to MTVA
Positive Phase 1 SAD safety and dose-linear pharmacokinetics data reported (September 2024) for DA-1726
Key milestone: Phase 2a trial data for DA-1241 (MASH) announced in December 2024 and Phase 1 MAD results for DA-1726 in Q1 2025
Part 3 obesity trial planned for Q3 2025 with interim data mid-2026 and top-line results H2 2026
Named Competitors
Ozempic/Wegovy — GLP-1 receptor agonist for obesity and diabetes
Mounjaro/Zepbound — GLP-1/GIP dual agonist for obesity and diabetes
Retatrutide — Triple GLP-1/GIP/glucagon agonist in development
GPR119 agonists — Competing MASH therapies
Recent Developments
(November 2024) Strategic realignment with corporate name change to MetaVia Inc. and ticker change to MTVA
(September 2024) Positive Phase 1 SAD Part 1 top-line data for DA-1726 obesity candidate
(June 2024) Financing of up to $70 million secured for clinical development
(June 2024) First patient dosed in DA-1726 Phase 1 MAD Part 2 obesity trial
Open the full interactive NeuroBo Pharmaceuticals, Inc. (now MetaVia Inc.) report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.